Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Income from Continuing Operations of 510000.0 for Q1 2026, up 99.5% year-over-year from 255635.47 in Q1 2025, and down 100.62% quarter-over-quarter from 81957000.0 in Q4 2025.
Powered by 
Analysis
Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Caris Life Sciences' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 510000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 99.5% year-over-year to 510000.0; the TTM figure through Mar 2026 stood at 33982000.0 (up 112.43% YoY), while the FY2025 annual figure was 68088000.0, up 75.85% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 510000.0, down from 81957000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 81957000.0 in Q4 2025, with the low at 102581000.0 in Q1 2025.
- The 3-year median for Income from Continuing Operations is 51566500.0 (2024), against an average of 29932625.0.
- Peak annual rise in Income from Continuing Operations reached 321.82% in 2025, while the deepest fall reached 8.47% in 2025.
- Caris Life Sciences' Income from Continuing Operations stood at 36947000.0 in 2024, then surged by 321.82% to 81957000.0 in 2025, then plunged by 100.62% to 510000.0 in 2026.
- Business Quant data shows CAI's Income from Continuing Operations at 510000.0 in Q1 2026, 81957000.0 in Q4 2025, and 24325000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Caris Life Sciences | 7.01 Bn | 6.22 Bn | 182.38 Mn | -637,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -637,000.00 |
| Mar 31, 2026 | -510,000.00 |
| Dec 31, 2025 | 81.96 Mn |
| Sep 30, 2025 | 24.33 Mn |
| Jun 30, 2025 | -71.79 Mn |
| Mar 31, 2025 | -102.58 Mn |
| Dec 31, 2024 | -36.95 Mn |
| Sep 30, 2024 | -67.73 Mn |
| Jun 30, 2024 | -66.19 Mn |